BackIntellia Therapeutics Overview
Intellia Therapeutics Inc

Intellia Therapeutics Target Price

Analysts' 12-month price predictions for NTLA.

Share Price

$8.31

Average Target Price

$17.50110.6% upside

2 analysts in the last 4 months

High: $26 | Low: $9

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2025-02-28Goldman Sachs$98.3% upsideOpen
2025-02-28Barclays$26212.9% upsideOpen
2024-11-11OppenheimerJay Olson$60622% upsideOpen
2024-10-24Robert W. BairdJack Allen$18116.6% upsideOpen
2024-08-09RBC CapitalLuca Issi$54549.8% upsideOpen
2024-06-24Stifel NicolausDae Gon Ha$80862.7% upsideOpen
2024-06-24Robert W. BairdJack Allen$24188.8% upsideOpen
2024-05-10BMO CapitalKostas Biliouris$70742.4% upsideOpen
2023-02-01Cantor Fitzgerald$67706.3% upsideOpen
2023-01-04Wells Fargo$1201344% upsideOpen
2022-12-06Credit Suisse$88959% upsideOpen
2022-12-02Leerink Partners$86934.9% upsideOpen
2022-11-15Chardan Capital$1291452.3% upsideOpen
2022-08-05Leerink Partners$1521729.1% upsideOpen
2022-08-05Chardan Capital$1461656.9% upsideOpen
2022-06-16BMO CapitalKostas Biliouris$54549.8% upsideOpen
2022-05-09JMP Securities$1101223.7% upsideOpen
2022-05-09Raymond JamesSteven Seedhouse$1051163.5% upsideOpen
2022-05-06Credit Suisse$981079.3% upsideOpen
2022-02-24RBC CapitalLuca Issi$1501705.1% upsideOpen
2022-02-18William BlairRaju Prasad$1441632.9% upsideOpen
2022-02-15Truist FinancialJoon Lee$1601825.4% upsideOpen
2022-02-03WedbushDavid Nierengarten$1081199.6% upsideOpen
2022-02-03Piper SandlerSwapnil Malekar$1711957.8% upsideOpen
2021-11-16Roth CapitalAnthony Butler$1802066.1% upsideOpen
2021-08-06Goldman SachsSalveen Richter$2522932.5% upsideOpen
2021-08-06Raymond JamesSteven Seedhouse$1812078.1% upsideOpen
2021-08-05BarclaysGena Wang$2072391% upsideOpen
2021-06-22JefferiesMaury Raycroft$1091211.7% upsideOpen